Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

71 results about "Palbociclib" patented technology

Palbociclib is used to treat a certain type of breast cancer in women.

Combination therapies for breast cancer

The present application discloses combinations for treating estrogen receptor-positive and HER2-positive breast cancer patients. The combinations comprise pertuzumab and trastuzumab (e.g. a fixed dose combination of pertuzumab and trastuzumab, PH FDC) plus giredestrant. In one embodiment, the combination further includes a CDK4 / 6 inhibitor, such as abemaciclib or palbociclib.
Owner:GENENTECH INC +1

PET tracer precursor compound targeting CDK4 / 6 receptor, PET tracer and preparation method and application of PET tracer

The invention provides a PET tracer precursor compound of a targeted CDK4 / 6 receptor and a preparation method and application of the PET tracer precursor compound, and further discloses a < 68 > Ga-labeled PET tracer. The PET tracer precursor compound is simple in preparation method, short in preparation time, high in radiochemical yield and suitable for industrial production. And the probe has the advantages of good in-vivo and in-vitro stability, high specificity, high intake and the like, and can be used for accurately and stably detecting and positioning tumor or inflammation parts. Besides, the PET tracer is a Ga-68-labeled targeted CDK4 / 6 radioactive probe synthesized on the basis of a compound Palbociclib, qualitative diagnosis of CDK4 / 6 in tumors can be achieved, then noninvasive accurate quantification of CDK4 / 6 in tumors is achieved, a reliable basis is provided in the stages of clinical staging, treatment decision making, curative effect monitoring and the like, and finally accurate diagnosis and treatment are achieved.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Combinations of nanoparticle-loaded immune agonists and ras targeted therapies for treatment of cancer

PCT designated stage expiredWO2024238486A2Organic active ingredientsAntineoplastic agentsStage tumorCD8
Described herein is the combination of STING / TLR4 agonist nanoparticles (NPs) and a combination of a MEK inhibitor (e.g., trametinib) and CDK4 / 6 inhibitor (e.g., palbociclib) treatment. This combination synergizes to (a) lead to enhanced NP uptake in multiple cell types in the TME, (b) increased antigen presentation on tumors cells as well as APCs, and (c) CD8+ T cell mediated long-term tumor control that is interferon signaling dependent. Also provided are methods to treat cancer, e.g., KRAS mutant cancers, e.g., KRAS mutant PDAC or lung cancer.
Owner:UNIV OF MASSACHUSETTS

Combination therapies for treatment of breast cancer

Provided are a combination therapy comprising inavolisib, palbociclib and fulvestrant and methods of treating PIC3CA-mutant, hormone receptor positive (HR+) and HER2 negative (HER2-) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib, palbociclib and fulvestrant. The combination therapy produces a statistically significant and clinically meaningful improvement to the patient as compared to administering palbociclib and fulvestrant alone to a comparable patient.
Owner:GENENTECH INC +3

Fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detecting and photodynamically removing senescent cells, and preparation method and application of fluorescent / photoacoustic dual-mode diagnosis and treatment probe

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.
Owner:HUNAN UNIV OF SCI & TECH +1

Selective CDK4 / 6 inhibitor cancer therapeutics

PendingAU2020406362B2Acyl groupOncology
The disclosure describes selective and potent CDK 4 / 6 inhibitors that show advantageous inhibition of cancer growth, even at low concentrations. A class of the CDK 4 / 6 inhibitors relates to substituted pyridopyrimidines compounds having a fatty acid moiety, and are namely derivatives of Palbociclib of general formula [2A], wherein R1 is hydrogen, aryl, alkyl, alkoxy, cycloalkyl, or heterocyclyl; R2 is hydrogen, halogen, alkyl, acyl, cycloalkyl, alkoxy, alkoxy alkyl, haloalkyl, hydroxy alkyl, alkenyl, alkynyl, nitrile, or nitro; R3 is hydrogen, halogen, alkyl, haloalkyl, hydroxy alkyl, or cycloalkyl; and n is an integer from 9 to 20. These compounds may be used as pharmaceutical compounds for anti-cancer therapies, and are useful for the treatment, prevention and / or amelioration of cancer.
Owner:LUNELLA BIOTECH INC

Combinations of nanoparticle-loaded immune agonists and ras targeted therapies for treatment of cancer

PCT designated stage expiredWO2024238486A3Sugar derivativesCarbohydrate active ingredientsStage tumorCD8
Described herein is the combination of STING / TLR4 agonist nanoparticles (NPs) and a combination of a MEK inhibitor (e.g., trametinib) and CDK4 / 6 inhibitor (e.g., palbociclib) treatment. This combination synergizes to (a) lead to enhanced NP uptake in multiple cell types in the TME, (b) increased antigen presentation on tumors cells as well as APCs, and (c) CD8+ T cell mediated long-term tumor control that is interferon signaling dependent. Also provided are methods to treat cancer, e.g., KRAS mutant cancers, e.g., KRAS mutant PDAC or lung cancer.
Owner:UNIV OF MASSACHUSETTS

Oral composition of palbociclib

The present invention relates to an oral composition of palbociclib or a pharmaceutically acceptable salt thereof useful for the treatment of advanced or metastatic breast cancer.
Owner:SAMYANG HLDG CORP

Combination therapies for treatment of breast cancer

ActiveTWI943875B
This invention provides a combination therapy comprising a PI3K inhibitor (e.g., epfuliximab), a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant; and a method for treating patients (preferably those with PIC3CA mutations) with hormone receptor-positive and HER2-negative (HR+ / HER2-) locally advanced or metastatic breast cancer, the method comprising administering a therapeutically effective amount of epfuliximab or a pharmaceutically acceptable salt thereof, a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.
Owner:GENENTECH INC

SELECTIVE CANCER THERAPEUTIC AGENTS CDK4 / 6 INHIBITORS

ActiveMX431671BAcyl groupOncology
The description discloses selective and potent CDK 4 / 6 inhibitors that exhibit advantageous inhibition of cancer growth, even at low concentrations. One class of CDK 4 / 6 inhibitors refers to substituted pyrrolopyrimidine compounds having a fatty acid moiety and specifically derived from Palbociclib of the general formula [2A], where R1 is hydrogen, aryl, alkyl, alkoxy, cycloalkyl, or heterocyclyl; R2 is hydrogen, halogen, alkyl, acyl, cycloalkyl, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, nitrile, or nitro; R3 is hydrogen, halogen, alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl; yn is an integer from 9 to 20. These compounds can be used as pharmaceutical compounds for anticancer therapies and are useful for the treatment, prevention and / or improvement of cancer.
Owner:LUNELLA BIOTECH INC

Methods for treating cancer

To provide methods for treating cancer.SOLUTION: Provided is a drug for inhibiting tumor growth or causing tumor regression in a subject with estrogen receptor alpha-positive breast cancer brain metastasis, the subject having one or more estrogen receptor alpha mutations selected from the group consisting of Y537S, Y537C, Y537N, D538G, and S463P. The drug comprises, as an active ingredient, a therapeutically effective amount of RAD1901 having a given structure, or a salt or solvate thereof, which is used in combination with palbociclib.SELECTED DRAWING: None
Owner:RADIUS PHARMACEUTICALS INC

Preparation method of key intermediate of anti-breast cancer drug palbociclib

The invention discloses a preparation method of an anti-breast cancer drug palbociclib key intermediate, and belongs to the field of medical technology synthesis. The preparation method comprises the following steps: reacting a compound VIII with N, O-dimethyl hydroxylamine in the presence of an organic solvent, alkali and a condensing agent to prepare a compound VII, and then carrying out nucleophilic substitution reaction, methylation reaction, Wittig-Horner reaction, bromination and oxidation reaction to prepare an intermediate compound I. The whole reaction route is shortened, the use of flammable and explosive organic metal reagents is avoided, the operability is strong, the method is green and environment-friendly, the total yield and purity of the product are improved, and the method is suitable for industrial mass production.
Owner:SHANDONG LUOXIN PHARMA GRP CO LTD +2

Bone marrow mononuclear cell cryopreservation liquid and method for recovering cell viability through cryopreservation at deep hypothermia

The invention provides a bone marrow mononuclear cell cryopreservation solution and a method for recovering cell viability through cryopreservation at a deep low temperature, and belongs to the technical field of cell cryopreservation. The method comprises the following steps: dividing bone marrow mononuclear cells into two parts, mixing one part with a cryopreservation solution containing Palbociclib, and performing cooling and cryopreservation to form cryopreserved bone marrow mononuclear cells; and culturing the other part of the cells until the primary cells grow to be full of the bottle bottom, and performing cryopreservation to form the cryopreserved bone marrow mesenchymal stem cells. When bone marrow mononuclear cells are resuscitated, firstly, cryopreserved bone marrow mesenchymal stem cells are resuscitated, and the mesenchymal stem cells BMSC-Evs are extracted; and then resuscitating the cryopreserved bone marrow mononuclear cells, and immediately adding mesenchymal stem cells (BMSC-Evs), so that the activity of the bone marrow mononuclear cells is recovered. According to the method, the survival rate of the recovered bone marrow mesenchymal stem cells reaches 80%, the recovery rate reaches 90%, the cell activity improvement rate is not lower than 30%, and the influence on the state of the recovered bone marrow mononuclear cells is small.
Owner:JINAN WANQUAN BIOTECHNOLOGY CO LTD

Combination therapy of hypoxia-responsive prodrug of an anticancer drug and radiotherapy, and novel hypoxia-responsive prodrug

A prodrug of an anticancer drug is used in combination therapy with radiotherapy. In the chemical formula (1), a moiety in which R1 and R2 bond to an N atom is a part of an anticancer drug having an amino group or an imino group with the amino group or the imino group removed, and the anticancer drug is selected from the group consisting of gemcitabine, niraparib, crizotinib, tabrafenib, vemurafenib, entinostat, cobimetinib, and palbociclib, ribociclib. Thereby, the side effects of the treatment, including radiotherapy, for malignant tumors are reduced or the treatment effect is enhanced.
Owner:UNIV OF TSUKUBA

CDK4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a CDK4 and 6 inhibitor

Disclosed are methods, uses, and combinations for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HIER2−) advanced or metastatic breast cancer in patients previously treated with a CDK4 and 6 inhibitor, the methods, uses, and combinations including the administration of a CDK4 and 6 inhibitor in combination with fulvestrant. The methods uses and combinations may include a CDK4 and 6 inhibitor such as palbociclib, ribociclib, or abemaciclib with fulvestrant.
Owner:ELI LILLY & CO

A method for synthesizing a palbociclib intermediate

The invention discloses a method for synthesizing a palbociclib intermediate, comprising the following steps: S1, under nitrogen protection, adding an intermediate 1, an organic base, vinyl n-butyl ether, and a catalyst into an organic solvent for reaction; S2, after the reaction is completed, adding an adsorbent to adsorb the catalyst, filtering, cooling and crystallizing; suction filtration, washing, and drying to obtain an intermediate 2. The present invention uses cheap raw material products with low cost, and all of them are conventional reagents that can be purchased on the market. At the same time, the synthesis method has simple process operation and post-processing, relatively mild reaction conditions, good product stability, and high yield and purity, and is suitable for industrial production.
Owner:JIANGSU CHUANGUO PHARMA CO LTD

Palbociclib-containing tablets

One embodiment of the present invention aims to provide a palbociclib tablet in which the formation of acetyl adducts of palbociclib is suppressed. [Solution] According to one embodiment of the present invention, a palbociclib-containing tablet is provided, comprising a core tablet containing palbociclib or a pharmaceutically acceptable salt thereof, and a film coat layer covering the core tablet, wherein the film coat layer contains an acetyl group-free plasticizer. The acetyl group-free plasticizer may be at least one selected from the group consisting of triethyl citrate, polyvinyl alcohol, polyethylene glycol, and hydroxypropyl cellulose.
Owner:SAWAI PHARMA

Bone marrow mononuclear cell freezing solution and method for cryopreservation and cell activity recovery

The present application provides a bone marrow mononuclear cell freezing solution and a method for deep-cryopreservation and cell activity recovery, which belongs to the field of cell cryopreservation technology. In this method, bone marrow mononuclear cells are divided into two parts, one part is mixed with a freezing solution containing Palbociclib, cooled and frozen to form frozen bone marrow mononuclear cells; the other part is cultured until the primary cells grow to cover the bottom of the bottle and frozen to form frozen bone marrow mesenchymal stem cells. When resuscitating bone marrow mononuclear cells, the frozen bone marrow mesenchymal stem cells are first resuscitated, and the mesenchymal stem cells BMSC-Evs are extracted; then the frozen bone marrow mononuclear cells are resuscitated, and the mesenchymal stem cells BMSC-Evs are immediately added to restore the activity of the bone marrow mononuclear cells. This method can achieve a survival rate of 80%, a recovery rate of 90%, and a cell activity improvement rate of not less than 30% after the resuscitation of bone marrow mesenchymal stem cells, and has little effect on the state of the revived bone marrow mononuclear cells.
Owner:JINAN WANQUAN BIOTECHNOLOGY CO LTD

Palbociclib dosage form

The present invention relates to a solid oral pharmaceutical dosage form comprising palbociclib as active pharmaceutical ingredient and succinic acid wherein the succinic acid has a surface area of more than 0.015 m2 / g.
Owner:ZHEJIANG KISUN PHARMACEUTICAL CO LTD +1

Method for treating tetra-negative breast cancer by inhibiting CYP1B1 through quercetin and combining with Palbociclib

The invention provides a method for treating tetra-negative breast cancer through combination of quercetin inhibiting CYP1B1 and Palbociclib, which comprises the following steps: verifying the influence of AR expression quantity on the curative effect of a CDK4 / 6 inhibitor in TNBC, screening related Chinese herbal medicine sets for treating TNBC by applying an HERB herbal medicine identification database, obtaining effective components and target spots thereof, analyzing the influence of quercetin inhibiting CYP1B1 expression in a QNBC cell line, and determining the curative effect of the CYP1B1 in the QNBC cell line. By knocking down an influence mechanism of CYP1B1 on AR expression in a QNBC cell line, analyzing a mechanism that the QNBC cell line is insensitive to Palbociclib and improving sensitivity, starting from the key target gene CYP1B1, how to improve the sensitivity of the QNBC cell line by regulating and controlling AR, Rb and other genes and related signal channels is deeply analyzed, so that the QNBC cell line is obtained. The multi-dimensional and multi-level research thought is beneficial to more comprehensive and deep understanding of the pathogenesis and the treatment target of QNBC; according to the present invention, the QNBC inhibition effect of quercetin is verified, and through the synergistic effect of the combination of the traditional Chinese medicine effective components and the clinical first-line western medicines, the new thought and the new drug selection are provided for the QNBC treatment, and the innovativeness and the practicability are provided;
Owner:WUHAN UNIV OF SCI & TECH

Multi-targeting photothermal-photodynamic-endocrine three-mode synergistic breast cancer treatment nano-drug and application thereof

The invention discloses a multi-targeting photothermal-photodynamic-endocrine three-mode synergistic breast cancer treatment nano-drug and application thereof, and relates to the technical field of biology and new medicine. Growth and metastasis of breast cancer cells are effectively inhibited through the synergistic effect of three modes of photo-thermal, photodynamic and endocrine therapy, the amphiphilic polymer designed based on Tcpp (tetracarboxylphenylporphyrin) can be self-assembled to form a nanoscale hollow regular sphere, and by means of the high permeability and retention effect (EPR effect) of a tumor site, the tumor site can be effectively inhibited, and the tumor site can be effectively inhibited. The efficient accumulation of the medicine in the tumor tissue is realized; the prodrug BHP is combined with a photo-thermal group and palbociclib, so that the synergistic interaction of multiple action mechanisms is realized, and the treatment effect is improved. The nano-drug prepared by the invention has good safety and biocompatibility, shows a remarkable anti-tumor effect in a tumor-bearing nude mouse model, and provides a brand new strategy and thought for treatment of breast cancer.
Owner:JIANGXI SCI & TECH NORMAL UNIV

Palbociclib-containing tablets

One embodiment of the present invention aims to provide a highly stable palbociclib tablet with improved dissolution properties and suppressed generation of related substances after storage under open conditions susceptible to humidity. [Solution] According to one embodiment of the present invention, a palbociclib-containing tablet is provided, comprising palbociclib or a pharmaceutically acceptable salt thereof, and at least one water-soluble acid, adipic acid, and ascorbic acid. The palbociclib-containing tablet may further contain succinic acid.
Owner:SAWAI PHARMA

A CDK4 / 6 inhibitor-loaded nano-carrier targeting breast cancer and preparation and application thereof

PendingCN122351194ANanocarriersA lipoprotein
This invention discloses a CDK4 / 6 inhibitor-loaded nanocarrier for targeting breast cancer, its preparation, and its application. Specifically, the nanoformulation of this invention contains: neutral phospholipids, anionic phospholipids, apolipoproteins and / or their mimic peptides, and a CDK4 / 6 inhibitor; wherein the CDK4 / 6 inhibitor is selected from the group consisting of abexicillin, ribociclib, palbociclib, dalcilib, or combinations thereof. The nanoparticles of this invention can efficiently kill breast cancer cells in vivo, inhibit breast cancer cell proliferation, and improve the prognosis of breast cancer.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Use of combination therapy for treatment of cancer

Disclosed herein are combination therapies for the treatment of cancer, the combination therapies comprising a WEE1 inhibitor compound A, also known as ZN-C3 or azeosertib, and any one of a CDK4 / 6 inhibitor (e.g., palbociclib)) or a HER-2 inhibitor (e.g., trastuzumab). In particular, the combination of the invention is intended for the treatment of breast cancer, such as triple negative breast cancer, ER + breast cancer, HER2 + breast cancer, and low HER2 breast cancer.
Owner:RECURIUM IP HLDG LLC

Use of cyclin-dependent kinase inhibitors in the treatment of heart failure with preserved ejection fraction

The present invention relates to the use of a cyclin-dependent kinase inhibitor for the treatment of heart failure with preserved ejection fraction. The use is in particular the use of the cyclin-dependent kinase (CDK4 / 6) inhibitor palbociclib for the prevention and / or treatment of heart failure with preserved ejection fraction by oral administration.
Owner:BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES

Application of alternatively spliced ​​transcripts in determining sensitivity to cell cycle drugs

The present invention belongs to the field of biomedicine, and specifically relates to the application of alternative splicing transcripts in determining the sensitivity of cell cycle drugs. To this end, the present invention provides the application of a reagent for detecting the expression amount of ENST00000547281 in the preparation of a product for determining the drug sensitivity of a patient to Palbociclib and Ribociclib.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Selective CDK 4 / 6 inhibitor cancer therapeutics

The disclosure describes selective and potent CDK 4 / 6 inhibitors that show advantageous inhibition of cancer growth, even at low concentrations. A class of the CDK 4 / 6 inhibitors relates to substituted pyridopyrimidines compounds having a fatty acid moiety, and are namely derivatives of Palbociclib of general formula [2A], wherein R1 is hydrogen, aryl, alkyl, alkoxy, cycloalkyl, or heterocyclyl; R2 is hydrogen, halogen, alkyl, acyl, cycloalkyl, alkoxy, alkoxy alkyl, haloalkyl, hydroxy alkyl, alkenyl, alkynyl, nitrile, or nitro; R3 is hydrogen, halogen, alkyl, haloalkyl, hydroxy alkyl, or cycloalkyl; and n is an integer from 9 to 20. These compounds may be used as pharmaceutical compounds for anti-cancer therapies, and are useful for the treatment, prevention and / or amelioration of cancer.
Owner:LUNELLA BIOTECH INC

A nano-drug for multiple targeting photothermal-photodynamic-endocrine triple-mode synergistic treatment of breast cancer and application thereof

The application discloses a kind of multiple targeting photothermal-photo dynamic-endocrine three-mode synergistic treatment breast cancer nano-drug and its application, it is related to biological and new pharmaceutical technical field.The application is effectively inhibited the growth and metastasis of breast cancer cell by the three-mode synergistic effect of photothermal, photo dynamic and endocrine therapy, amphiphilic polymer based on Tcpp (four carboxyl phenyl porphyrin) It can be self-assembled to form nanoscale hollow regular sphere, using the high permeability and retention effect (EPR effect) of tumor site, realize the efficient accumulation of drug in tumor tissue;Prodrug BHP is realized by combining photothermal group and palbociclib, and the synergistic effect of multiple action mechanisms, so as to improve the treatment effect.The nano-drug prepared by the application has good safety and biocompatibility, and exhibits significant antitumor effect in tumor-bearing nude mouse model, which provides a new strategy and idea for the treatment of breast cancer.
Owner:JIANGXI SCI & TECH NORMAL UNIV